Dermira announces positive topline results from phase 2b study of lebrikizumab in patients
Dermira announced positive results from a Phase 2b dose-ranging study of lebrikizumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis. All three doses of lebrikizumab met the primary endpoint, demonstrating greater improvements in EASI score versus placebo. March 18, 2019